Anodyne Nanotech

Anodyne Nanotech is pioneering a transdermal delivery platform, the HeroPatch, designed to deliver large-molecule therapeutics such as biologics and peptides without needles. Founded in 2019, the company is targeting high-value chronic conditions like obesity and sarcopenia, aiming to improve patient convenience, reduce costs, and enable new therapeutic formulations. With a seasoned leadership team and a clinical-stage pipeline, Anodyne is positioning itself as a potential disruptor in the drug delivery space through both internal development and strategic partnerships.

The HeroPatch, a transdermal delivery platform utilizing solid-form APIs and nanoscale physics to enable tunable, needle-free delivery of multi-milligram doses of biologics and peptides with room-temperature stability.

Anodyne competes in the broad needle-free drug delivery space, which includes companies developing oral biologics, inhaled formulations, and other transdermal technologies like microneedle patches (e.g., Vaxxas, Corium). Its direct transdermal patch competitors include established players like Noven (acquired by Hisamitsu) and LTS Lohmann, though these have traditionally focused on small molecules.